Pliant Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Pliant Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PLRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001746473
- EIN
- 47-4272481
Board of directors
-
Bernard Coulie · Director · President and CEOSince 2023
-
Darren S. Cline · DirectorSince 2023
-
David E. I. Pyott · DirectorSince 2023
-
Flavia Borellini · DirectorSince 2026
-
Gayle A. Crowell · DirectorSince 2023
-
Hoyoung Huh · DirectorSince 2023
-
John T. Curnutte · DirectorSince 2023
-
Katharine Knobil · DirectorSince 2023
-
Robert Iannone · DirectorSince 2026
-
Smital Shah · DirectorSince 2023
-
Steve E. Krognes · DirectorSince 2024
-
Suzanne Louise Bruhn · DirectorSince 2023
-
Thomas A. Mccourt · DirectorSince 2023
Chief executives
Bernard Coulie
· President and CEO
Dates unknown
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
59.4%
Board connections
12 of this board's directors also sit on 17 other boards.
- via Hoyoung Huh
- via David E. I. Pyott
- via Robert Iannone
- via David E. I. Pyott
- via Suzanne Louise Bruhn
- via Steve E. Krognes
- via Steve E. Krognes
- via Gayle A. Crowell
- via Thomas A. Mccourt
- via Katharine Knobil
- via Smital Shah
- via Katharine Knobil
- via Darren S. Cline
- via Flavia Borellini
- via Bernard Coulie
- via David E. I. Pyott
- via Suzanne Louise Bruhn
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $163,620
- 4 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 20, 2026 | Cummings Keith Lamont Officer (Chief Financial Officer) | Open-market sale | −24,002 | $1.28 | $30,723 |
| Jan 20, 2026 | Cheung Lily Officer (Chief Human Resource Officer) | Open-market sale | −7,534 | $1.28 | $9,644 |
| Jan 20, 2026 | Bernard Coulie Director, Officer (President and CEO) | Open-market sale | −89,375 | $1.28 | $114,400 |
| Jan 20, 2026 | Kuo Minnie Officer (Chief Operating Officer) | Open-market sale | −6,917 | $1.28 | $8,854 |
| Jan 23, 2025 | Cheung Lily Officer (Chief Human Resource Officer) | Grant or award | +25,875 | — | — |
| Jan 23, 2025 | Ouimette Mike Officer (General Counsel & Corp. Sec'y) | Grant or award | +35,000 | — | — |
| Jan 23, 2025 | Hull Hans Officer (Chief Business Officer) | Grant or award | +40,150 | — | — |
| Jan 23, 2025 | Lefebvre Eric Officer (Chief Medical Officer) | Grant or award | +45,650 | — | — |
| Jan 23, 2025 | Cummings Keith Lamont Officer (Chief Financial Officer) | Grant or award | +56,650 | — | — |
| Jan 23, 2025 | Bernard Coulie Director, Officer (President and CEO) | Grant or award | +162,500 | — | — |
| Jan 22, 2025 | Ouimette Mike Officer (General Counsel & Corp. Sec'y) | Open-market sale | −10,230 | $10.99 | $112,428 |
| Jan 17, 2025 | Bernard Coulie Director, Officer (President and CEO) | Open-market sale | −52,419 | $11.20 | $587,093 |
| Jan 17, 2025 | Cummings Keith Lamont Officer (Chief Financial Officer) | Open-market sale | −20,148 | $11.20 | $225,658 |
| Jan 17, 2025 | Hull Hans Officer (Chief Business Officer) | Open-market sale | −15,936 | $11.20 | $178,483 |
| Jan 17, 2025 | Lefebvre Eric Officer (Chief Medical Officer) | Open-market sale | −18,478 | $11.20 | $206,954 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.